EGFR and non-small cell lung carcinoma: In this article, we review the most relevant scientific evidence of continuing the systemic therapy with the same EGFR-TKI, with or without other agents, for the management of patients with NSCLC harboring EGFR mutations and oligoprogressed to first-line EGFR-TKIs, also discussing the controversies and potential future directions.